How is the supply chain for immunotherapies impacted by COVID-19? 15-Apr-2020 By Ben Hargreaves COO of Dendreon explains how ‘every part’ of the supply chain for the company’s lead product has been affected by the novel coronavirus.
Dendreon extends lease on cell therapy plant to 2030 21-May-2019 By Nick Taylor Dendreon Pharmaceuticals has extended the lease on its immunotherapy manufacturing facility in California through to 2030.